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Abstract
Current therapies for most non-infectious diseases are directed at or affect functionality of the human translated genome, 
barely 2% of all genetic information. By contrast, the therapeutic potential of targeting the transcriptome, ~ 70% of the 
genome, remains largely unexplored. RNA therapeutics is an emerging field that widens the range of druggable targets and 
includes elements such as microRNA. Here, we sought to screen for microRNA with tumor-suppressive functions in neuro-
blastoma, an aggressive pediatric tumor of the sympathetic nervous system that requires the development of new therapies. 
We found miR-323a-5p and miR-342-5p to be capable of reducing cell proliferation in multiple neuroblastoma cell lines 
in vitro and in vivo, thereby providing a proof of concept for miRNA-based therapies for neuroblastoma. Furthermore, the 
combined inhibition of the direct identified targets such as CCND1, CHAF1A, INCENP and BCL-XL could reveal new 
vulnerabilities of high-risk neuroblastoma.
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Introduction
Approximately 15,000 new cases of pediatric cancers are 
diagnosed yearly in Europe, with around 10% corresponding 
to neuroblastoma (NB), an embryonal tumor of the sympa-
thetic nervous system [1]. NB accounts for 15% of all can-
cer-related deaths in children, and is the embryonal tumor 
with the lowest 5-year relative survival [2]. Significant 
improvements are only foreseen in the field of new targeted 
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therapies and personalized medicine programs which, at pre-
sent, are effective for a small number of patients. Therefore, 
new approaches must be considered.
RNA therapeutics is an emerging field that widens the 
range of druggable targets and includes elements such as 
small interference RNA (i.e., siRNA, shRNA and micro-
RNA). MicroRNA (miRNA) are small non-coding RNA that 
interfere with the translation and stability of coding mRNA 
in a sequence-specific manner [3]. Mounting evidence shows 
miRNA to be deregulated and functionally contributing to 
the development and progression of different human can-
cers, including NB [4, 5]. An overall reduction in miRNA is 
observed in advanced NB, mainly due to alterations in the 
miRNA-processing machinery [6]; therefore, miRNA res-
toration represents an attractive novel therapeutic approach.
To identify miRNA with therapeutic potential in NB, we 
carried out high-throughput functional screening of 2048 
miRNA mimics. Several miRNA with potential tumor-
suppressive functions were identified, among which miR-
323a-5p and miR-342-5p had the highest therapeutic poten-
tial in multiple NB cell lines in vitro and in vivo. These 
results support the use of miRNA-based restoration therapies 




SK-N-AS, SH-SY5Y, IMR-32 and HEK293T cell lines 
were purchased from American Type Culture Collection 
(ATCC, Manassas, VA, USA), CHLA-90 cell line from the 
Children’s Oncology Group Cell Culture and Xenograft 
Repository (Lubbock, TX, USA). SK-N-BE(2) and LA1-5s 
acquired from Public Health England Culture Collections 
(Salisbury, UK). All cell lines purchased from the tissue 
banks were amplified and stored in liquid nitrogen. Upon 
resuscitation, cells were maintained in culture for no more 
than 2 months. SK-N-AS, SK-N-BE(2), SH-SY5Y, IMR-
32, CHLA-90 and LA1-5s were cultured and maintained in 
Iscove’s modified Dulbecco’s medium (Life Technologies, 
Fig. 1  Functional high-throughput miRNA screening identified sev-
eral tumor-suppressive miRNA. a Screening design. b Graph repre-
senting the effects of 2048 individual miRNA on cell proliferation. 
The percentage of growth inhibition was obtained by comparing the 
average of three independent miRNA mimics replicates with mock-
transfected cells and standardized using the Z score transformation 
method. MiRNA previously reported as tumor-suppressive miRNA in 
NB are indicated. c Pie chart representing the genomic distribution 
of miRNA that were capable of reducing cell proliferation ~ 50% (Z 
score < − 2)
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Thermo Fisher Scientific) supplemented with 10% heat-inac-
tivated fetal bovine serum (South America Premium, Bio-
west) and 1% of insulin–transferrin–selenium Supplement 
(Life Technologies, Thermo Fisher Scientific). HEK293T 
were grown in Dulbecco’s modified Eagle’s medium (Life 
Technologies, Thermo Fisher Scientific) supplemented with 
10% heat-inactivated fetal bovine serum. All media were 
supplemented with 100 U/mL penicillin, 100 µg/mL strep-
tomycin (Life Technologies, Thermo Fisher Scientific) and 
5 μg/mL plasmocin (InvivoGen). All cultures were main-
tained at 37 °C in a saturated atmosphere of 95% air and 5% 
 CO2. All cell lines were frequently tested for mycoplasma 
contamination.
MicroRNA functional high‑throughput library 
screening
Chemoresistant SK-N-BE(2) cells were seeded in 96-well 
plates at 5000 cells/well using the MultidropV2 dis-
penser (Finstruments). Twenty-four hours later cells were 
transfected with a microRNA library consisting of 2048 
human miRNA mimics (Dharmacon, Lafayette, CO, USA, 
 miRIDIAN® microRNA Library—Human Mimic (19.0) 
CS-001030 Lot 13112, GE Healthcare, 25 nM each miRNA) 
in technical triplicates using Lipofectamine 2000 (Life tech-
nologies, Thermo Fisher Scientific, Madrid, Spain, 0.2 µL 
per well) using the Robotic Platform Caliper Sciclone (Cali-
per Life Sciences, Perkin Elmer, Waltham, Massachusetts, 
USA). At 96-h post-transfection, cells were fixed with 1% 
glutaraldehyde (Sigma-Aldrich) and stained with 0.5% crys-
tal violet (Sigma-Aldrich, Madrid, Spain). Crystals were dis-
solved with 15% acetic acid (Fisher Scientific) and absorb-
ance was measured at 590 nm using an Epoch Microplate 
Spectrophotometer (Biotek, Winooski, Vermont, USA).
Screening statistics
Data quality control and analysis of different factors (e.g., 
miRNA position, transfection time) was performed using 
“R” Statistical Software (Supplementary Fig. 1C).
The absorbance value of each mock- or miRNA-trans-
fected well was normalized to the median of all non-
transfected values of the corresponding replicate plate. To 
evaluate the effect of each miRNA on cell proliferation, the 
absorbance value (3 replicates) versus the median of all 
mock values was compared. The statistical significance was 
assessed by Student’s t test and the p value was adjusted by 
the false discovery rate “FDR” method. The percentage of 
Fig. 2  Ectopic expression of miRNA located at 14q32 reduced cell 
proliferation in multiple NB cell lines. a Heatmap representing effects 
of the indicated miRNA on cell proliferation reduction in MYCN 
amplified (MNA) and MYCN non-amplified (non-MNA) cell lines. 
The overexpression effect of each miRNA on cell proliferation was 
compared to mock-transfected cells. b, d Relative expression  (log2) of 
miR-342 (b) and miR-323a (d) in MNA and non-MNA NB tumors. c, 
e Overall survival Kaplan–Meier plot of the indicated miRNA expres-
sion in human NB tissues
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 , where x is the value of cell proliferation after trans-
fection of each single miRNA, µ is the mean cell prolifera-
tion of all miRNA and σ the standard deviation.
Mouse xenograft
SK-N-AS cells (4 × 106) were reverse transfected with 
25 nM of miR-control, miR-323a-5p or miR-342-5p in 100-
mm plates (25 µL lipofectamine/dish). SK-N-BE(2) cells 
(4.7 × 106) were reverse transfected with 25 nM of miR-
control, miR-323a-5p or miR-342-5p in T175 flasks (90 µL 
lipofectamine/flask). Thirty-six hours post-transfection, 
4 × 106 cells/flank of SK-N-AS and 5 × 106 cells/flank of SK-
N-BE(2) were injected into the right flank of 6- to 8-week-old 
female NMRI-nude mice (n = 13 mice/condition of SK-N-AS 
and n = 15 mice/condition of SK-N-BE(2)) (Janvier Labs, Le 
Genest-Saint-Isle, France) in 300 µL of PBS:Matrigel (1:1). 
Tumor volume was measured every 2–3 days. At the end 
of the experiment, the primary tumors were removed and 
weighted. Part of the tumors were fresh frozen and the rest 
fixed in 10% formalin and embedded in paraffin.
Statistical methods
Unless otherwise stated, mean ± SEM values are repre-
sentative of the average of three independent experiments. 
Statistical significance was determined by unpaired two-
tailed Student’s t test (GraphPad Prism Software, La Jolla, 
CA, USA.). * Means p < 0.05, ** means p < 0.01 and *** 
means p < 0.001.
Results
Functional high‑throughput miRNA screening 
identified several miRNA with tumor‑suppressive 
activity
High-throughput screening using the largest library of 
miRNA mimics available was performed to identify miRNA 
with tumor-suppressive functions in NB. Individual miRNA 
mimics were transfected into the SK-N-BE(2) cells (Fig. 1a). 
Control miRNA (i.e., cel-miR-67 and cel-miR-239b) were 
used as negative controls and miR-497-5p as a positive con-
trol [7, 8] (Supplementary Fig. 1a,b). The overexpression of 
52 miRNA was found to reduce ~ 50% cell proliferation (Z 
score < − 2, adjusted p value < 0.05) (Fig. 1b; Supplemen-
tary Tables 1, 2).
Since it has been suggested that miRNA with similar 
functions cluster together [9], we examined the genomic 
distribution of miRNA whose overexpression produced 
the highest reduction on cell proliferation. Interestingly, 7 
of the 52 miRNA (13.5%) were located at 14q32 (Fig. 1c 
and Supplementary Table 2), a locus with high miRNA 
density and frequently lost or silenced in different types 
of tumors, including NB [10].
Restoration of miRNA located at 14q32 reduced cell 
viability in multiple NB cell lines
The tumor-suppressive effects of miRNA hits located at 
14q32 (i.e., miR-380-5p, miR-665, miR-541-3p, miR-
299-3p, miR-654-5p, miR-323a-5p and miR-342-5p) 
were further confirmed in an extended panel of six NB 
cell lines bearing genomic alterations associated with 
resistance to standard NB therapies and poor patient out-
come (Supplementary Table 3). The overexpression of all 
miRNA tested reduced cell proliferation in multiple NB 
cell lines compared with mock- and miR-control-trans-
fected cells being miR-323a-5p and miR-342-5p those 
ones with the highest therapeutic potential (Fig. 2a).
Low miR‑323a‑5p expression levels correlate 
with poor patient outcome
The expression levels of miR-323a-5p and miR-342-5p 
were analyzed in a large cohort of NB tissue samples and 
correlated with clinical parameters. Whereas lower expres-
sion levels of miR-342-5p did not correlate with the clinical 
parameters analyzed (Fig. 2b–c), low miR-323a-5p levels 
were found to correlate with MYCN genomic amplification 
(Fig. 2d) and shorter overall survival (Fig. 2e).
Ectopic expression of miR‑323a‑5p and miR‑342‑5p 
halted cell cycle progression and induced apoptosis 
in NB
To clarify whether the reduction in cell number upon miR-
323a-5p and miR-342-5p overexpression was due to inhibi-
tion of cell proliferation and/or induction of cell death, cell 
cycle progression was analyzed using flow cytometry. The 
overexpression of miR-323a-5p induced a modest increase 
Fig. 3  MiR-323a-5p induced cell cycle arrest at G0/G1 phase. Cell 
cycle flow cytometry analysis of the indicated cell lines transfected 
with miR-control, miR-323a-5p or miR-342-5p at 25 nM for 96 h. a 
One representative histogram of three independent experiments. b, c 
Histograms representing the average percentage of living cell popula-
tion from three independent experiments of SK-N-BE(2) (b) or SK-
N-AS (c) cells in G0/G1, S, or G2/M phases. *p < 0.05, **p < 0.01, 
two-tailed Student’s t test. d, e Western blot of the indicated cell cycle 
regulatory proteins in SK-N-BE(2) (d) and SK-N-AS (e) transfected 
with miR-control, miR-323a-5p and miR-342-5p (25 nM) at 72 h and 
96 h post-transfection
◂
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Fig. 4  MiR-323a-5p and miR-342-5p overexpression induced apop-
tosis in NB cells. a, b Analysis of chromatin fragmentation/conden-
sation in SK-N-BE(2) (a) and SK-N-AS (b) transfected with 25 nM 
of miR-control, miR-323a-5p or miR-342-5p 96  h post-transfection. 
Images on the right show a representative field of NB cells stained 
with Hoechst dye. White arrowheads point to cells with condensed 
and/or fragmented chromatin. Data represent mean  ±  SEM of 
three independent experiments (n = 3 per experiment). *p < 0.05, 
**p < 0.01, two-tailed Student’s t test. c, d Representative Western 
blot analysis of apoptosis-related proteins in SK-N-BE(2) (c) and SK-
N-AS (d) transfected with miR-control, miR-323a-5p or miR-342-5p 
(25 nM) at 72 h and 96 h post-transfection
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in the subG1 peak and an increment in G0/G1-phase popula-
tion accompanied by a reduction in the S and G2/M phases. 
Therefore, both cell cycle arrest and increased cell death 
might be contributing to the miR-323a-5p overexpression 
phenotype (Fig. 3a–c). Concurring with these observations, 
a reduction in cyclins, D1, E1 and B1 was observed after 
miR-323a-5p overexpression at 72 h post-transfection and 
a consequent reduction in phospho-RB levels at later time 
points. Furthermore, upregulation of the cell cycle inhibitor 
p27 was also observed (Fig. 3d, e).
MiR-342-5p-transfected cells showed no apparent dif-
ferences regarding cell cycle progression compared to 
miR-control cells, but did show an accumulation of cells in 
subG1, thereby indicating cell death induction (Fig. 3a–c). 
In this case, reduced levels of cyclins, D1, E1 and B1 
and phospho-RB, but not increased p27 levels, were also 
observed (Fig. 3d, e), suggesting that cells committed to die 
were unable to progress through the cell cycle.
Next, we examined the chromatin status of miRNA-
transfected cells by Hoechst staining. MiR-323a-5p and 
miR-342-5p transfected cells showed a higher percentage 
of cells with condensed and fragmented chromatin stain-
ing, one of the typical hallmarks of apoptosis (Fig. 4a, b). 
Furthermore, NB cells transfected with miR-323a-5p and 
miR-342-5p showed cleavage of the executor caspase-3 and 
one of its targets α-FODRIN, both indicative of apoptotic 
cell death (Fig. 4c, d).
MiR‑323a‑5p and miR‑342‑5p target cell cycle 
and survival genes
To find the downstream mediators of miR-323a-5p and miR-
342-5p phenotypic effects in NB, a miRNA-target analysis 
was performed comparing five different platforms (Fig. 5a, 
b). For miR-323a-5p, 905 potential targets were predicted 
by at least four independent algorithms, whereas 1380 
were predicted for miR-342-5p (Supplementary Tables 4, 
5). According to the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway analysis [11], a significant 
number of these predicted targets were associated with cell 
cycle or commonly altered pathways in cancer (Fig. 5c, d, 
p value < 0.05). These genes were selected for validation 
based on their expression association with NB outcome 
and/or previous reported functional role in cancer (Sup-
plementary Tables 6, 7). Transient miRNA overexpression 
proved to consistently reduce the mRNA levels of several 
miR-323a-5p (i.e., CHAF1A, KIF11, INCENP, CDC25A, 
CCND1, FADD and E2F2) and miR-342-5p (i.e., AKT2, 
CCND1, MKNK2 and BCLX) predicted targets (Supple-
mentary Fig. 2a–d). To confirm the reduction also in pro-
tein levels, Western blot was performed at 48 h and 72 h 
post-transfection of miR-323a-5p or miR-342-5p. CHAF1A, 
KIF11, INCENP, CDC25A, CCND1 and FADD protein 
levels decreased in both cell lines when cells were trans-
fected with miR-323a-5p (Fig. 5e). On the other hand, only 
CCND1 and BCL-XL protein levels were reduced in both 
cell lines when cells were transfected with miR-342-5p, 
whereas no differences were found in AKT2 levels. Results 
for MKNK2 were not conclusive (Fig. 5f).
To ascertain whether the potential targets were regulated 
directly by miR-323a-5p or miR-342-5p, we engineered 
luciferase-reporter vectors with the 3′UTR of genes bearing 
the putative miRNA-binding sites (Supplementary Fig. 3). 
The reporter vectors were co-transfected with a miR-con-
trol, miR-323a-5p or miR-342-5p and luciferase activity 
was quantified 24 h after transfection. The overexpression 
of miR-323a-5p caused a reduction in luciferase activity in 
the CHAF1A, INCENP, CCND1 and FADD 3′UTR reporter 
vectors and no differences were observed for KIF11 and 
CDC25A, thereby indicating that these last two genes are not 
direct targets (Fig. 5g). On the other hand, reduction in the 
luciferase activity of CCND1 and BCLX 3′UTR vectors by 
miR-342-5p overexpression confirmed both genes as direct 
miR-342-5p targets (Fig. 5h).
CCND1, CHAF1A and INCENP silencing mostly 
reproduced miR‑323a‑5p overexpression effects
The contribution of each target to the miRNA overexpression 
phenotype was analyzed by siRNA-mediated gene silenc-
ing. Silencing of CHAF1A, KIF11 and CCND1 showed 
a reduction in cell proliferation similar to that induced by 
miR-323a-5p, while INCENP and FADD silencing only 
produced a moderate effect (Fig. 6a). Western blot analysis 
72 h post-transfection confirmed siRNA efficacy (Fig. 6a, 
lower panels). Overall, CCND1 depletion mirrored the best 
miR-323a-5p overexpression, not only the general effects 
on cell proliferation, but also on the reduction in phospho-
RB levels and p27 accumulation (Fig. 6b). However, when 
apoptosis induction was analyzed, CHAF1A and INCENP 
were the direct targets that better phenocopied the effects of 
miR-323a-5p overexpression (Fig. 6c). These results suggest 
that the combination of CCND1, CHAF1A and INCENP 
inhibition is sufficient to reproduce the therapeutic effects 
of miR-323a-5p.
Inhibition of CCND1 and BCL‑XL partially reproduces 
the effects of miR‑342‑5p
The same strategy was used to characterize the contribu-
tion of miR-342-5p targets. In this case, only the inhibition 
of CCND1 showed a similar reduction in cell proliferation 
(Fig. 6d). In agreement with this observation, only CCND1 
silencing caused a reduction in phospho-RB levels and 
accumulation of the cell cycle inhibitor p27 (Fig. 6e). How-
ever, apoptosis induction was not observed with silencing 
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of either CCND1 or BCL-XL (Fig. 6f) suggesting that the 
observed effects of miR-342-5p on cell death might require 
the inhibition of both or additional targets.
MiR‑323a‑5p and miR‑342‑5p overexpression 
reduced tumor growth in vivo
We proceeded to validate the capacity of miR-323a-5p and 
miR-342-5p to reduce tumor growth in vivo by subcutaneous 
injection of SK-N-BE(2) or SK-N-AS cells previously trans-
fected with miR-control, miR-323a-5p or miR-342-5p into 
the flank of NRMI-nude mice. At the end of the experiment, 
all groups showed a similar percentage of tumor incidence 
(~ 80–100%, Fig. 7a, e), which suggested that miRNA over-
expression did not interfere with tumor engraftment. Tumor 
growth was monitored every 2–3 days for 28 days for SK-N-
BE(2) or 18 days for SK-N-AS. While in SK-N-AS, only the 
overexpression of miR-342-5p was capable of delaying cell 
growth in vivo, both miRNA were effective in SK-N-BE(2) 
cells, showing a final ~ twofold reduction in tumor growth at 
the end of the experiment (Fig. 7b, f). These effects were con-
firmed by the analysis of tumor weight (Fig. 7c, d, g, h-Sup-
plementary Fig. 4a, b).
In summary, our results confirm miR-323a-5p and miR-
342-5p as potential therapeutic tools against high-risk NB. Of 
note, miR-323a-5p overexpression impaired tumor growth in 
the MYCN-amplified cell line, but not in SK-N-AS, suggest-
ing that higher doses of miR-323a-5p or being functional for 
longer periods of time may be needed to achieve a therapeutic 
effect. In support of this hypothesis, miRNA levels were ana-
lyzed at the beginning and at the end of experiment. Both cell 
lines achieved similar levels of miRNA overexpression at the 
time of injection (Supplementary Fig. 5a, c) ruling out the 
possibility of differential transfection efficiency between cell 
lines. However, at the end of experiment, SK-N-AS maintained 
much lower levels of miR-323a-5p in SK-N-AS but not in 
SK-N-BE(2) (Supplementary Fig. 5b, d), thus suggesting that 
this miRNA is processed faster in this cell line and therefore, 
tumor cells overcome more easily the miR-323a-5p tumor-
suppressive effects.
Discussion
Despite the emerging personalized medicine programs for 
pediatric tumors, which include molecular profiling of NB, 
the small number of recurrent somatic mutations found at 
diagnosis and the lack of established tumor drivers, limit the 
therapeutic opportunities for NB patients. On the other hand, 
some patients relapse and develop drug resistance when 
treated with anticancer drugs targeting single molecules, 
which might be due to the activation of alternative pathways.
MiRNA alterations have been shown to participate in 
the progression and outcome of NB (reviewed in [12]). 
We propose the use of miRNA as multi-target approach to 
overcome treatment resistance in NB patients, given that 
a single miRNA can inhibit multiple targets involved in 
tumorigenic processes.
Multiple pharmaceutical companies have already 
included miRNA in their developmental drug pipelines 
(e.g., miR-34 [13, 14], miR-16 [15], miR-122 [16]). The 
first challenge in applying this approach to the treat-
ment of high-risk NB is to identify those miRNA with 
the highest therapeutic potential. Our work is the largest 
high-throughput functional screening performed to date to 
identify miRNA with tumor-suppressive functions in can-
cer and particularly for NB. Of the 2048 miRNA tested, we 
identified 52 that significantly reduced cell proliferation 
with a Z score lower than − 2 (~ 50% of cell proliferation). 
Concurring with previous reports, multiple tumor-suppres-
sive miRNA such as members of the let-7 miRNA tumor-
suppressive family (e.g., let-7i-5p, let-7a-3p, let-7f-2-5p, 
let-7g-5p or let-7e-3p [17, 18]) were also identified in our 
screening, thereby validating our approach to identifying 
tumor-suppressive miRNA.
Notably, 7 of the 52 miRNA (13.5% of the total) shown 
to reduce cell proliferation ~ 50% are encoded in the 14q32 
genomic region. This region is frequently altered in cancer 
and particularly in NB [10], which raises the possibility 
that this region contains tumor-suppressor genes. All 7 
miRNA identified in our screening showed the capacity to 
reduce cell proliferation in multiple NB cell lines in vitro, 
with miR-323a-5p and miR-342-5p being those with the 
highest therapeutic potential.
In agreement with our results, miR-323a-5p has been 
reported to be downregulated in NB patients with MYCN 
amplification and associated with unfavorable outcome 
[19, 20]. Moreover, miR-323a-5p overexpression has been 
reported to reduce proliferation and promote apoptosis of 
human cerebral glioma cells [21]. We found that ectopic 
expression of miR-323a-5p suppressed cell growth through 
Fig. 5  MiR-323a-5p and miR-342-5p modulated the expression of 
multiple cancer-related genes. a, b Venn diagram representing the 
overlap of predicted target genes among five miRNA-target predic-
tion algorithms of miR-323a-5p or miR-342-5p. c, d Representation 
of the functional annotation of predicted target genes of miR-323a-5p 
(c) or miR-342-5p (d) using KEGG pathways and Gene Ontology 
databases. Red bars indicate selected pathways to analyze potential 
miRNA targets. e, f Representative Western blot of predicted target 
genes in SK-N-BE(2) and SK-N-AS transfected with miR-control, 
miR-323a-5p (e) or miR-342-5p (f) at 48 h and 72 h post-transfection. 
g, h Luciferase 3′UTR reporter assays. Graph represents luciferase 
activity in HEK-293T cells co-transfected with 50 ng/well of the indi-
cated reporter vectors and 25 nM of miR-control, miR-323a-5p (g) or 
miR-342-5p (h). Data represented the average ± SEM of three inde-
pendent experiments (n = 3 per experiment). *p < 0.05, **p < 0.01, 
***p < 0.001
◂
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Fig. 6  MiRNA target-knockdown partially reproduced the anti-
tumoral effects of miR-323a-5p and miR-342-5p. a, d Cell viability 
assay of SK-N-BE(2) and SK-N-AS transfected with 25 nM of miR-
323a-5p, miR-342-5p or the indicated siRNA. Target protein knock-
down was analyzed by Western blot at 72 h post-transfection (lower 
panels). b, e Expression of some representative cell cycle regulatory 
proteins in SK-N-BE(2) and SK-N-AS transfected with miR-323a-5p, 
miR-342-5p or the indicated siRNA (25  nM) at 96  h post-transfec-
tion. c, f Western blot analysis of apoptosis-related proteins in SK-
N-BE(2) and SK-N-AS transfected with miR-323a-5p, miR-342-5p 
or the indicated siRNA (25 nM) at 96 h post-transfection. Graph rep-
resents one of three independent experiments (n = 6 per experiment). 
Asterisk compares miR-323a-5p or miR-342-5p versus miR-Control 
and hash compares each siRNA versus control siRNA. * or #p < 0.05, 
** or ##p < 0.01, *** or ###p < 0.001, two-tailed Student’s t test
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the direct modulation of several cell cycle-associated 
genes such as CCND1, CHAF1A, INCENP and FADD 
and caused a G1 cell cycle arrest followed by induction 
of apoptosis. The silencing of the miR-323a-5p direct 
targets CHAF1A, INCENP and CCND1 were those that 
more closely recapitulate the phenotypic effects of miR-
323a-5p overexpression. CCND1 is a well-established 
oncogene frequently overexpressed and associated with 
poor outcome in different types of tumors including NB 
[25]. CCND1 interacts with CDK4 and CDK6 and the 
activation of this complex phosphorylates RB and other 
transcription factors which promote cell cycle progression 
[26]. To date, the best approach to targeting CCND1 is 
through the use of CDK4/6 inhibitors such as palbociclib, 
ribociclib and abemaciclib.
Although the best known functions of CCND1 are 
related to cell cycle control, CCND1 has CDK-independ-
ent functions. For example, CCND1 regulates cell differ-
entiation by binding to several transcription factors such 
as the estrogen receptor α (ERα) and the androgen recep-
tor (AR) (reviewed in [27]). Therefore, a direct inhibition 
of CCND1 could be therapeutically more effective than 
CDK4/6 inhibition.
Another of the newly identified relevant miR-323a-5p 
target is CHAF1A, a chromatin modifier protein recently 
involved in maintaining the undifferentiated state of highly 
aggressive NB [28]. Thus, in addition to halting cell cycle 
progression, miR-323a-5p could also be relevant for NB 
therapy through repressing the expression of genes that 
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Fig. 7  MiR-323a-5p and MiR-342-5p overexpression reduced tumor 
growth in  vivo. a, e Tumor formation incidence in SK-N-BE(2) (a) 
and SK-N-AS (e). b, f Tumor growth of xenografts derived from 
SK-N-BE(2) (b) SK-N-AS (f) cells transfected with miR-control, 
miR-323a-5p or miR-342-5p. Tumor measurements were taken three 
times per week for ~  3  weeks. c, g Representative images of dis-
sected tumors (bar indicates 1  cm). d, h Tumor weight at 18  days 
post-injection. Hash compares miR-323a-5p versus control and aster-
isk compares miR-342-5p versus control. * or #p < 0.05, **p < 0.01, 
***p < 0.001, two-tailed Student’s t test
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The silencing of INCENP phenocopied the apoptosis 
induction of miR-323a-5p overexpression. INCENP (inner 
centromere protein) is a component of the chromosomal pas-
senger complex (CPC), a complex that regulates mitosis. 
INCENP is a scaffolding subunit for the CPC and activates 
Aurora B kinase [29]. Similar to CHAF1A, high levels of 
INCENP in primary NB tumors are associated with poor 
prognosis (Supplementary Table 6). In addition, silenc-
ing of INCENP using doxycycline-inducible shRNA led 
to significant decreases in growth of NB xenografts and 
increases mice survival (Sun et al. Advances in Neuroblas-
toma Research 2018). Therefore, targeting INCENP could 
be a novel promising therapy in NB.
Our in vivo studies suggested that the transient overex-
pression of miR-323a-5p was enough to halt the proliferation 
of MYCN-amplified NB cells but not in SK-N-AS xenograft 
models, probably due to a higher rate of miRNA processing. 
At that point, and owing to technical limitations, the fact that 
more sustained overexpression of miR-323a-5p could have a 
better therapeutic response cannot be ruled out.
In contrast, the transient overexpression of miR-342-5p did 
show faster induction of cell death in vitro and a clear reduc-
tion in tumor growth in vivo in both NB xenografts tested. In 
line with our observations, miR-342-5p was reported to be 
downregulated in breast cancer patients with early relapse 
[22] and was able to reduce HER2-positive breast cancer cell 
growth [23] and colon cancer cells [24].
Interestingly, we found that miR-342-5p is also a direct 
modulator of CCND1. CCND1 silencing alone caused a dra-
matic decrease in NB cell proliferation, but was not enough 
to induce cell death (Fig. 6c, f). We also identified BCL-XL 
as a direct target of miR-342-5p. BCL-XL is an anti-apop-
totic member of the B cell lymphoma 2 (BCL-2) protein fam-
ily whose overexpression contributes to tumor progression 
and resistance to chemotherapeutic agents [30]. Although 
BCL-XL reduction alone only causes a minimal reduction 
in cell number and did not induce cell death (Fig. 6f), it may 
lower the threshold of apoptosis induction upon CCND1 
silencing or inhibition. Therefore, the concomitant reduction 
in CCND1 and BCL-XL would more faithfully reproduce 
the overexpression effects of miR-342-5p.
Conclusions
Our strategy is confirmed as valid for the identification of 
novel tumor-suppressive miRNA such as miR-323a-5p and 
miR-342-5p in NB models, including but not limited to the 
ones that are resistant to conventional therapies and reveals 
new vulnerabilities of high-risk NB through the combined 
inhibition of targets such as CCND1, CHAF1A, INCENP 
and BCL-XL.
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